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Abstract 
 
A human kinome screen identified kinase suppressor of ras-1 (KSR1) as a regulator of estrogen 
receptor α (ERα) and recent studies suggest that KSR1 may have dual functions as a scaffold 
protein and as a kinase. Although KSR1 has been implicated in Ras-dependent tumors, its role 
in breast cancer has not been investigated. In multivariate analyses high KSR1 expression was 
significantly associated with longer DFS (p=0.014) and OS (p=0.012). Interestingly, KSR1 was 
associated positively with BRCA1 (p=0.002) and inversely with p53 levels (p=0.038). MCF7-
KSR1 stable cell line had a significant decreased number of colonies and formed smaller size 
colonies compared to MCF7-parental cells. Our in vivo mouse model demonstrated that 
xenografts tumor volumes over-expressing KSR1 were significantly reduced compared to 
controls. SILAC analysis revealed various novel KSR1-regulated proteins and phospho-
proteins. Mechanistically, over-expression of KSR1 decreases the transcriptional activity of p53 
by reducing the phosphorylation of DBC1, which leads to a reduced interaction of DBC1 with 
SIRT1 therefore allowing SIRT1 to deacetylate p53. Moreover, KSR1 stabilizes BRCA1 protein 
levels by up-regulating BARD1 expression and promoting the interaction between BRCA1 and 
BARD1. Our data link these factors in a continuum with clinical relevance and positions KSR1 in 
the major oncoprotein pathways in breast tumorigenesis. 
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Estrogen regulates breast cancer growth through the action of the estrogen receptor alpha 
(ERα) and therapies targeting this pathway have transformed treatment. Despite this, 1-1.5% of 
women diagnosed with primary breast cancer subsequently relapse each year, highlighting the 
need for the discovery of new regulatory targets and mechanisms implicated in this process 1,2. 
We have previously performed a short interfering RNA (siRNA) screen and identified a number 
of protein kinases whose silencing alters the estrogen genomic response in breast cancer cells 
3. Amongst them was kinase suppressor of ras 1 (KSR1), initially described as a novel protein 
kinase functioning either downstream of RAS or on a parallel pathway to RAF by a genetic 
screening 4-7. KSR1, a ceramide-activated proline-directed serine-threonine kinase has been 
shown to directly phosphorylate and activate Raf-1 but also serves as a scaffold for the Raf-1-
mitogen-activated protein kinase (Mek)-extracellular signal-regulated kinase (Erk)-mitogen-
activated protein kinase pathway 8-10. KSR1 has been extensively referred to as a 
pseudokinase, owing to the fact that there is controversy regarding whether its kinase domain is 
active, as suggested in one recent study 11, or it serves as a scaffold protein to organize 
spatiotemporal regulation of the ERK cascade 12, or perhaps both. Such findings add significant 
complexity to the simple view of ERK pathway control and identify pseudokinases such as 
KSR1 as potential therapeutic targets. 
The function of KSR1 in human disorders has been undefined although KSR1-deficient mice are 
prone to colitis 13 but on the other hand fail to develop arthritis 14; it also recruits inducible nitric 
oxide (NO) synthase and heat shock protein-90 to release NO during pulmonary infection 15. 
Previous studies reported that KSR1 regulates the proliferative and oncogenic potential of cells 
and inhibition of KSR1 abrogates Ras-dependent pancreatic cancer 16,17. However, as Ras gene 
mutations are rare in breast cancer, it is similarly unclear whether the role of KSR1 is similar to 
its role in Ras-dependent cancers 18, and its biologic function in this setting is unexplored, as are 
its major partner proteins and pathways including those connected to p53 and BRCA1, both of 
which we implicate here.  
The p53 tumor suppressor is well known to play a central role in cell growth arrest, apoptosis 
and cellular response to genotoxic stress 19,20. Its transcriptional activity is highly regulated by 
post-transcriptional modifications including acetylation 21,22. Previous data showed that deleted 
in breast cancer 1 (DBC1) directly interacts and negatively regulates the deacetylase SIRT1 
resulting in an increase of p53 acetylation 23,24. Recent evidence describe that phosphorylation 
of DBC1 is necessary for its interaction with SIRT1 while it inhibits the activity of SIRT1 in 
response to DNA damage 25,26. BRCA1 tumor suppressor gene mutations contribute to a 
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proportion of hereditary breast and ovarian cancers 27. BRCA1 forms a heterodimer with the 
BRCA1-associated ring domain 1 (BARD1) protein, which was discovered in a yeast two-hybrid 
screen as a binding partner of BRCA1 28. Later work suggested that BARD1 stabilises BRCA1 
by inhibiting its ubiquitination 29,30.   
Herein, we initially evaluated the clinical significance of KSR1 in a large cohort of breast cancer 
patients and found a significant association of KSR1 with overall and disease free survival. We 
next established that high KSR1 expression inhibits tumor growth both in vitro and in vivo.Using 
SILAC technique we identified novel proteins that are regulated by KSR1 in breast cancer cells. 
In aggregate, we describe a novel role of KSR1 on the regulation of p53 acetylation and BRCA1 
ubiquitination. 
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Results 
KSR1 is an independent predictor of overall survival in breast cancer.  
To investigate the clinical significance of KSR1 in breast cancer patients, tissue microarrays 
(TMAs) containing > 1000 primary operable breast cancer cases from the previously validated 
Nottingham Tenovus Primary Breast Carcinoma Series were employed. Cytoplasmic KSR1 
abundance in breast cancer tissues was determined by immunohistochemistry in accordance to 
its expression levels (Figure 1a). High KSR1 levels were significantly associated with longer 
overall survival (p = 0.012; Figure 1b) and an increased disease free survival (p = 0.014; 
Figure 1c) in a 240 months follow-up. KSR1 was not predictive of response to endocrine 
therapy (p = 0.064; Figure 1d) or adjuvant chemotherapy (p = 0.096; Figure 1e). In addition, no 
significant association of KSR1 with main breast cancer biomarkers was observed (Table 1). 
However, high KSR1 was associated with high BRCA1 (p = 0.002; table 1) and low p53 levels 
(p = 0.038; table 1). Multivariate Cox-proportional hazards analysis revealed KSR1 as an 
independent prognostic factor (table 2). We also identified two intronic KSR1 polymorphisms 
(rs2241906 and rs1075952) but they were not correlated with either disease free or overall 
survival (Figure S1). Finally, we performed an Oncomine 31 analysis of KSR1 gene expression.  
From 28 analyses based on 11 datasets, there were four32-35 with a significant p value (p<0.05) 
and gene rank in the top 18% among all differentially expressed genes. In all of these cases, 
KSR1 was consistently up-regulated in normal breast tissue compared to invasive cancers 
(Figure S2).  
 
KSR1 over-expression inhibits tumor formation and growth in vitro and in vivo. 
Based on the significance of KSR1 in primary breast cancer, we decided to take a ‘bedside to 
bench’ approach and examine the role of KSR1 in vitro. Analysis of the gene and protein 
expression levels of KSR1 in a panel of breast cancer cell lines showed that KSR1 is 
ubiquitously expressed at various levels (Figure S3). In accordance with our clinical cohort 
observation (table 1) there was no association between the expression levels of KSR1 and ERα 
status.  
Following, we investigated the role of KSR1 in growth and colony formation of breast cancer 
cells. For this reason, we generated an MCF7 cell line stably over-expressing KSR1 (MCF7-
KSR1; Figure S4) and performed a 3D Matrigel-overlay assay, which allows integration of the 
extracellular matrix signalling components. Over-expression of KSR1 significantly reduced the 
size of the large and loose aggregates formed by the MCF7 parental cells (Figure 2a). Similar 
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results were observed in the soft agar assay, where the total number and size of cell colonies 
was analyzed. MCF7-KSR1 cells derived a significantly lesser number of smaller colonies 
compared to MCF7 parental cells (Figure 2b, p < 0.001). 
We also explored the effects of KSR1 over-expression on tumor growth in vivo after 
subcutaneous transplantation of MCF7-KSR1 (or MCF7-parental cells) into nude mice. The 
tumour volumes of breast cancer xenografts over-expressing KSR1 were markedly reduced 
compared with the control group (Figure 2c). Immunohistochemical analyses of tumor tissues 
showed that the Ki67 proliferation index was strongly decreased in MCF7-KSR1 mice showing 
abundant KSR1 expression (Figure 2d).Collectively, both our in vitro and in vivo results 
demonstrate the anti-proliferative role of KSR1 further validating its pro-survival contribution in 
breast cancer patients. 
 
Identification of KSR1-regulated proteins using SILAC. 
 
KSR1 has been extensively referred to as a pseudokinase, since there is controversy regarding 
whether its kinase domain is active 11 or instead if it serves as a scaffold protein 12 or even 
perhaps both.  
Considering the clinical importance of KSR1 and since its role in breast cancer is poorly 
understood, we decided to investigate and identify novel proteins (phosphorylated or not) that 
are differentially regulated by KSR1. For this reason, we performed a quantitative proteomic 
analysis by stable isotope labelling of amino acids in cell culture. MCF7 cells were grown for 7 
cell divisions in either R0K0 ‘light’ medium, containing unlabelled [12C6,14N4]-arginine (Arg) and 
[12C6]-lysine (Lys) amino acids, or in R10K8 ‘heavy’ medium, containing labelled [13C6,15N4]-Arg 
and [13C6]-Lys. Following, R0K0 and R10K8 labelled cells were transfected with either empty 
vector (pCMV6, control) or with a plasmid encoding for full length KSR1 (pCMV6-KSR1), 
respectively.  After 24h, total protein extracts were prepared, mixed 1:1, digested, fractionated, 
subjected to LC-MS/MS and analysed using MaxQuant 36 (Figure S5).  
A total of 2504 proteins were identified with either 1 peptide (n1=424) or a minimum of 2 
peptides (n≥2=2080), both with a false discovery rate of 1%. Out of these proteins, 2032 were 
quantified (≥1 peptide) and their distribution according to fold changes was determined (Figure 
3a). Gene ontology classification according to biological and molecular functions, and STRING 
analysis to identify networks associated with increased or decreased KSR1-regulated proteins 
was performed, using a cut-off of log2 ratio >0.5 or <-0.5, (Tables S1 and S2 and Figures S6 
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and S7).A significance B (Sig B) p-value 36was calculated in order to identify significant outliers 
(proteins) from the background population (Figure 3b and Table S3).  
In order to validate the SILAC proteomic results, we performed Western blotting on selected 
proteins that were significantly modulated (up or down) after KSR1 over-expression (Fig 3c). 
We also performed an analysis to identify changes in the phosphorylation status of proteins 
after KSR1 overexpression; a total of 1407 phosphopeptides were identified out of which, 1165 
were quantified (Tables S4 and S5; cut-off of log2 ratio >0.15 or <-0.15). Values from the two 
independent experiments (total and phosphorylated proteins) were plotted to create a graph 
showing the log2 normalised ‘total proteins’ versus the log2 ‘phosphorylated proteins’ ratios 
(Figure 3d).  Detailed information for each identified protein, including protein ID’s, number of 
peptides used for identification and their sequence and % coverage, normalised fold changes 
and log2 ratios are listed in Excel file S1. 
 
KSR1 decreases p53 acetylation by reducing phosphorylation of DBC1 resulting in 
impaired interaction between DBC1 and SIRT1. 
Taking into consideration our clinical data demonstrating a link between KSR1 and p53 / 
BRCA1 expression, we decided to focus our work on clarifying the connection of KSR1 with 
these two bona fide tumor suppressors. We firstly assessed the effects of KSR1 on p53 
transcriptional activity by performing luciferase reporter assays using various p53-dependent 
gene promoter constructs (including p53-R2, p53-AIP1, p53-IGFBP3 and p53-CYCLIN G1). 
MCF7 cells were co-transfected with either pCMV6 or pCMV6-KSR1plasmids and each 
individual p53-dependent promoter construct, in the presence or absence of etoposide, which 
can induce p53 activity. Interestingly, the luciferase activity of all four different p53-regulated 
genes was significantly repressed after over-expression of KSR1 (basal levels and after 
etoposide treatment; Figure 4a). 
In order to investigate the potential mechanism resulting in the down-regulation of p53 
transcriptional activity, we initially evaluated the p53 gene and protein expression after KSR1 
over-expression. RT-qPCR and western blotting analyses did not reveal any changes in the p53 
mRNA and protein levels respectively after KSR1 over-expression in MCF7 cells (Figure 4b). 
Since the nuclear localisation of p53 is essential for its activity, we examined whether KSR1 
could affect p53 compartmentalisation. Immunofluorescence analysis and subcellular protein 
fractionation did not reveal any cytoplasmic translocation of p53 upon KSR1 over-expression 
(Figure 4b). Moreover, it has been recently reported that neddylation of p53 can inhibit its 
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transcriptional activity 37,38. However, our neddylation assay did not show any significant 
changes following KSR1 over-expression ruling neddylation as the reason for the observed p53 
decreased activity (Figure S8).  
Post-translational modifications of p53 such as phosphorylation and acetylation are essential for 
p53 activity in response to genotoxic stress 21,22. Therefore, to examine effects of KSR1 on 
phospho-p53 and acetylated-p53, MCF7 cells were transfected with pCMV6 or pCMV6-KSR1 
plasmids in the presence of etoposide or doxorubicin. While the phosphorylation levels of p53 
(Ser15) did not change, interestingly the acetylated-p53 was reduced after KSR1 over-
expression upon either etoposide (Figure 4c) or doxorubicin (Figure S9a) treatment. Moreover, 
KSR1 silencing rescued the abolished acetylation of p53 after etoposide treatment (Figure 4d). 
Similar results were confirmed in several other cancer cell lines (including ZR75-1, SKBR3 and 
HCT116; Figure S9b).  
Total protein levels of SIRT1, which is linked to de-acetylation of p53 31 were not affected by 
KSR1 up-regulation (Figure 4c). However, according to our SILAC data, amongst the most 
significantly KSR1-regulated phosphorylated proteins, was ‘deleted in breast cancer 1’ (DBC1), 
whose involvement in the regulation of p53 activity and SIRT1 has been previously described 
23,24. Western blotting analysis of DBC1 at Thr454 revealed a decrease in the phosphorylation 
levels in basal and etoposide-induced conditions (Figure 4c). Consistently, knock-down of 
KSR1 did not alter the total proteins of SIRT1 and DBC1, but increased DBC1 phosphorylation 
at Thr454 (Figure 4d).Finally, since phosphorylated DBC1 interacts stronger with SIRT1 
inhibiting its ability to de-acetylate p53 25,26, we tested whether KSR1 affects the stress-induced 
SIRT1-DBC1 interaction resulting in the downstream effects on p53 activity. As shown in Figure 
4e, upon etoposide treatment, the interaction between SIRT1 and DBC1 was undermined after 
KSR1 over-expression in MCF7, supporting our proposed model that KSR1 is able to inhibit 
DBC1 phosphorylation resulting in less binding to SIRT1 promoting p53 de-acetylation. 
 
KSR1 stabilizes endogenous BRCA1 by specifically reducing BRCA1 ubiquitination. 
Based on the positive correlation between KSR1 and BRCA1 expression on our clinical cohort, 
we assessed the effects of KSR1 on BRCA1 in vitro. Over-expression of KSR1 in MCF7 cells 
increased BRCA1 protein without altering its mRNA levels, while KSR1 silencing resulted in a 
decrease of BRCA1 protein (Figure 4f). Similar effects were observed in ZR75-1 cells (Figure 
S8c). 
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Since KSR1 appears to regulate BRCA1 at the protein level, we investigated the involvement of 
KSR1 on BRCA1 ubiquitination. MCF7 cells treated with different proteasome inhibitors (MG115 
and MG132) revealed that KSR1 over-expression resulted in abundant BRCA1 protein levels 
independent of treatment, while there was a decrease in the ubiquitination of BRCA1 upon over-
expression of KSR1 (Figure 4g). It is already known that BRCA1 forms a heterodimeric 
complex with BARD1 that promotes its stabilisation by reducing its ubiquitination, Our western 
blotting results revealed that up-regulation of KSR1 causes an increase of BARD1 protein while 
KSR1 silencing decreases the expression of BARD1 (Figure 4h). Furthermore, 
immunoprecipitation evidence indicated that the interaction between BRCA1 and BARD1 was 
strengthened after KSR1 over-expression (Figure 4h). Collectively, our data suggest that KSR1 
can stabilize BRCA1 protein by enhancing the interaction between BRCA1 and BARD1, which 
consequently decreases its ubiquitination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KSR1 and breast cancer 
 
10 
 
Discussion  
 
KSR1 was first identified more than 15 years ago as a novel protein kinase implicated in the 
Ras-Raf pathway: defects in KSR1 inhibits activated Ras, without affecting the pathways 
induced by activated Raf 39,40. Interestingly, low levels of KSR1 enhance Ras-induced activity, 
whereas high KSR1 expression can suppress the Ras pathway 16. Emerging evidence suggest 
that KSR1 possess dual activity as a scaffold protein and as active kinase phosphorylating Raf-
1 and MEK1 9-11. Moreover, KSR1 can also form dimers with Raf modulating its activity 41,42. 
Considering the role of KSR1 in Ras-Raf-MAPKs signalling, research has focused on 
investigating the involvement of KSR1 in Ras-dependent cancers, including skin 43, pancreatic17 
and lung carcinomas 44.Its clinical significance and biologic functions in breast cancer have not 
been examined.  
Our previous work identified KSR1 as a prospective regulator of ERα signaling 3. In this study, 
we establish a role of KSR1 as an independent prognostic indicator in breast cancer associating 
it with a better overall and disease free survival in a large patient cohort (n=1000) with >20 
years follow-up. This is the first report to demonstrate a protective role for KSR1 in cancer, as 
thus far it has been linked to tumor growth induction in pancreatic and lung cancer 17, indicative 
of a contrasting tissue specific mechanism of function in different biologic contexts. In 
agreement with our clinical observations, Oncomine analysis revealed that KSR1 gene 
expression is reduced in different breast cancer dataset, while as expected is up-regulated in 
lung and colorectal cancers partly due to abnormally activated/mutated Ras signalling pathway.  
Following a novel ‘bedside to bench’ approach, we investigated the biological role of KSR1 in 
vitro and in vivo. The physiologically relevant 3D-Matrigel overlay assay, which integrates 
signals from the extracellular matrix was performed, showing a decrease in the number and size 
of acini structures formed by KSR1 over-expressing MCF7 cells. To further address the effect of 
KSR1 on the tumorigenic potential of breast cancer cells, we performed a soft agar assay, 
where KSR1-MCF7 cells colony formation was significantly compromised. Moreover, results 
from breast cancer mice xenografts revealed that KSR1 abundance markedly inhibits tumor 
growth, further supporting the positive clinical significance of KSR1. We also identified novel 
KSR1-regulated proteins and signalling networks that KSR1 is involved in, apart from the 
classical Ras-Raf-MAPKs pathway, by performing a SILAC experiment. The observation that 
KSR1 expression is associated with low p53 and high BRCA1 in breast cancer tissues was 
further investigated. Interestingly, KSR1 over-expression suppressed p53 transcriptional activity 
KSR1 and breast cancer 
 
11 
 
by reducing the acetylation of p53, while silencing of KSR1 had the opposite effects. It is already 
known that SIRT1 is able to deacetylate p53 22,45 while DBC1 can interact with and negatively 
regulate SIRT1 resulting in increased p53 acetylation 23,24. Moreover, phosphorylation of DBC1, 
induced by genotoxic stress, enhances the interaction between SIRT1 and DBC1 25,26. Our 
SILAC data and further in vitro experiments using a number of relevant cell lines (MCF7, ZR75-
1, SKBR3 and HCT116), demonstrated that KSR1 over-expression decreases the 
phosphorylation of DBC1, attenuating the interaction of SIRT1-DBC1 leading to declined p53 
acetylation.  
The correlation between KSR1 and BRCA1 in breast cancer tissues pinpoints the potential role 
of KSR1 in tumor suppression. Our in vitro results showing increased BRCA1 levels after KSR1 
over-expression are in accordance with the clinical findings. We also determined that KSR1 
increases BARD1 protein, which has been previously reported to form a heterodimer with 
BRCA1 thereby stabilising it by reducing its ubiquitination 29. Moreover, KSR1 over-expression 
enhanced the interaction between BRCA1 and BARD1, which is important for tumor inhibition in 
breast cancer as previously described 28.  
Taken together, we propose a model (Figure 5) where KSR1 is implicated in a dynamic 
interplay involving p53 and BRCA1 and present in vitro, in vivo and clinical evidence that 
indicate the tumor suppressor functions of KSR1 and its prognostic significance in breast 
cancer. Since the role of KSR1 as a kinase and/or as a scaffold protein still remains 
controversial, further investigation is needed to elucidate which of these features are required 
for the observed results presented herein. Finally, the identification of novel KSR1-regulated 
proteins will shed light on new KSR1-modulated signalling pathways implicated in breast 
cancer.  
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Figure legends 
Figure 1. Association of KSR1 expression with clinical outcome in breast cancer. a) 
Immunohistochemistry staining (IHC) of paraffin embedded breast cancer tissues for KSR1 
expression. Representative images of staining intensities: i) negative, ii) 1+, iii) 2+ and iv) 3+. 
Images were adopted from the high resolution digital imaging (NanoZomer,Hamamatsu 
Photonics, Welwyn Garden City, UK) with a web-based interface (Distiller, Slide-Path Ltd., 
Dublin, Ireland) Magnification, x 100. b) Kaplan-Meier survival curves for KSR1 expression 
levels with overall survival (High = 278, Low = 527; p = 0.012) and disease free survival (High = 
325, Low = 620; p = 0.012) in a 240 months follow-up. c) Kaplan-Meier overall survival curves 
for KSR1 expression levels with response to endocrine therapy (High = 101, Low = 171; p = 
0.064) and to chemotherapy (High = 58, Low = 97; p = 0.096) in a 240 months follow-up. 
 
Figure 2. Effects of stable over-expression of KSR1 on breast cancer tumour growth in 
vitro and in vivo. a) 3-D Matrigel overlay assay. MCF7-parental or MCF7-KSR1 cells were 
embedded in Matrigel and cultured for 10 days in 10% FCS DMEM supplemented with 2% 
Matrigel. Phase contrast images of representative acini structures were taken at Day 10. Scale 
bar, 50 µm. b) Soft agar growth assay. MCF7-parental or MCF7-KSR1 cells were incubated for 
14 days in soft agar. Optical sections of representative colonies are shown. Scale bar, 50 µm. 
Colonies from soft agar assay were counted in 5 random fields per well. Diameters of colonies 
were measured and grouped as (≤75 µm, 75-100 µm and 100 µm). Bar chart shows data of 
three independent experiments, mean ± SD (*p<0.001). c) Breast cancer xenograft model in 
BalbC nude mice. 5×106 MCF7-vector or MCF7-KSR1 cells were injected subcutaneously in the 
flanks of nude mice (n = 8). Tumor volume was measured every 3 days using callipers. Growth 
curves shown are mean tumour ± SD. Representative set of xenografts derived from MCF7-
parental or MCF7-KSR1 cells are shown. d) Representative IHC analyses for KSR1 and Ki67 
on paraffin-embedded section of xenografts derived from MCF7-parental or MCF7-KSR1 cells.  
Figure 3. Protein identification and quantification of KSR1-regulated proteins using 
SILAC. a) Distribution of 2033 identified KSR1-regulated proteins according to log2 ratios. b) 
Significance B (Sig B) testing of KSR1-regulated proteins, after examining the ratio and intensity 
based p-value that indicates the probability that specific proteins are significant outliers from the 
background population. c)  d) Graph highlighting the outliers within the phospho-peptides data 
that may be of interest as they do not fall into the general gradient of 1 (indicated by the red 
line). The ratio’s that do fall within this gradient have equivalent regulation levels as their un-
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phosphorylated counter-peptides and any differences in regulation are explained by an 
equivalent regulation in the non-phospho experiment. (The outliers show a different regulation 
from the non-phospho expt peptides and the treatment they both underwent, indicating there is 
a genuine increase in phosphorylation stoichiometry within these peptides.)   
 
Figure 4. Mechanisms of KSR1-regulated p53 transcriptional activity and BRCA1 
ubiquitination. a) Effects of KSR1 over-expression on p53 transcriptional activity in the 
presence or absence of etoposide by luciferase assays. MCF7 cells were transiently co-
transfected with either pCMV6 (vector) or pCMV6-KSR1 plasmids in the presence of four 
individual p53-dependent promoter constructs expressing firefly luciferase genes (p53-R2, p53-
AIP1, p53-CYCLIN G1, and p53-IGFBP3) following DMSO or etoposide (40μM) treatment for 
3h. Firefly luciferase activity was measured (renilla luciferase activity was used to normalize 
transfection efficiency). The normalized luciferase activity of empty vector is set as 1. Results 
shown are the average of at least three independent experiments and error bars represent SD. 
b) Effects on mRNA, total protein and subcellular localization of p53 after KSR1 over-
expression. MCF7 cells were transiently transfected with pCMV6 (vector) or pCMV6-KSR1 
plasmids for 24 hours. Total mRNA and protein were extracted as described in Materials and 
Methods. Subsequently, relative mRNA levels of TP53 and p53 total protein were measured by 
qRT-PCR and western blotting, respectively. Gene expression level from cells transfected with 
pCMV6 was set as 1. Results shown are the average of at least three independent experiments 
and error bars represent SD. Protein fractions from the nucleus and cytoplasm were extracted 
as described in Materials and Methods. Rb and Tubulin expression served as positive 
normalising control for nuclear and cytoplasmic proteins respectively. Immunofluorscence 
staining of p53 in MCF7 cells after 24 hours transfection with either pCMV6 or pCMV6-KSR1 
plasmids. p53 was detected with an anti-p53 antibody while the nucleus was stained with DAPI. 
Representative pictures of three independent experiments are shown. c) Effects on p53 
acetylation and phosphorylation of DBC1 after KSR1 over-expression followed by a 
titration of etoposide treatment. MCF7 cells were transiently transfected with pCMV6 (vector) 
or pCMV6-KSR1 plasmids for 24 hours Following, cells were treated with various concentration 
of etoposide (20, 40, 80 µM, 3h). p53 acetylation and DBC1 phosphorylation at Thr454 were 
assessed by immunoblotting with specific antibodies as indicated. d) Effects on p53 
acetylation and phosphorylation of DBC1 after KSR1 silencing followed by a titration of 
etoposide treatment. MCF7 cells were transfected with control siRNA (siCT) or siKSR1 for 72 
hours followed by etoposide treatment (20, 40, 80 µM, 3h). p53 acetylation and DBC1 
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phosphorylation at Thr454 were assessed by immunoblotting with specific antibodies as 
indicated.) e) Interaction of DBC1 and SIRT1 after KSR1 over-expression with etoposide 
treatment by immunoprecipitation. MCF7 cells were transiently transfected with pCMV6 or 
pCMV6-KSR1 plasmids for 24 hours. Subsequently, cells were treated with etoposide (40µM, 
3h). The interactions between SIRT1 and DBC1 were detected by immunoprecipitation (IP) of 
SIRT1 or DBC1 followed by immunoblotting with DBC1 and SIRT1 antibodies respectively. f) 
Effects of KSR1 over-expression and silencing on BRCA1 mRNA and protein levels. 
MCF7 cells were transiently transfected with pCMV6 or pCMV6-KSR1 plasmids for 24 hours. 
For knock-down of KSR1, MCF7 cells were transfected with either control siRNA (siCT) or 
siKSR1 for 72 hours. Total mRNA and protein were extracted as described in Materials and 
Methods. Subsequently, relative mRNA levels of BRCA1 gene were measured by qRT-PCR. 
Gene expression level from cells transfected with pCMV6 was set as 1. Results shown are the 
average of at least three independent experiments and error bars represent SD. The protein 
expression levels of BRCA1 was assessed by western blotting. g) Effects of KSR1 over-
expression on BRCA1 ubiquitination. MCF7 cells were transiently transfected with pCMV6 or 
pCMV6-KSR1 plasmids for 24 hours, in the presence or absence of MG115 or MG132 
proteasome inhibitor (10 µM, 6h). BRCA1 protein levels were assessed by immunoblotting with 
specific antibodies as indicated. Ubiquitination of BRCA1 was detected by immunoprecipitation 
of BRCA1 followed by immunoblotting with ubiquitin antibody. h) Effects of KSR1 over-
expression on BARD1 protein levels and the interaction between BRCA1 and BARD1. 
MCF7 cells were transiently transfected with pCMV6 or pCMV6-KSR1 plasmids for 24 hours. 
For knock-down of KSR1, MCF7 cells were transfected with either control siRNA (siCT) or 
siKSR1 for 72 hours. The protein expression levels of BARD1 were assessed by western 
blotting. The interactions between BRCA1 and BARD1 were detected by immunoprecipitation 
(IP) of BRCA1 followed by immunoblotting with BARD1 antibody. 
All blots shown are representatives of at least three independent experiments (* p<0.05; ** 
p<0.01; ***p<0.001). 
 
Figure 5 Schematic illustration of a dynamic interplay between KSR1, p53 and BRCA1 in 
breast cancer. A novel model indicating the role of KSR1 on p53 and BRCA1 is proposed here: 
a) KSR1 reduces DBC1 phosphorylation resulting in a decreased interaction of DBC1 with SIRT 
allowing SIRT1 to deacetylate p53, which leads to a down-regulation of p53 transcriptional 
activity. b) KSR1 stabilizes BRCA1 protein by increasing BARD1 protein levels enhancing the 
interaction between BRCA1 and BARD1, which in turn decreases ubiquitination of BRCA1.  
KSR1 and breast cancer 
 
16 
 
Supplementary Figure legends 
Figure S1 Correlations of KSR1 polymorphisms with overall survival and disease free 
survival in breast cancer patients. Kaplan-Meier curves demonstrate the association between 
two KSR1 polymorphisms: a) rs2241906 and b) rs1075952 and overall survival (p1 = 0.3841; p2 
= 0.4710) and disease-free survival (p1 = 0.2481; p2 = 0.3529). 
 
Figure S2 Oncomine data-mining analysis of KSR1 mRNA in breast cancer. Comparison of 
KSR1 mRNA expression between normal breast tissue versus invasive ductal breast carcinoma 
in 4 different datasets. 
 
Figure S3 Expressions of KSR1 gene and protein levels in various breast cancer cell 
lines. a) KSR1 mRNA levels were measured by qRT-PCR. KSR1 expression in MCF7 is set as 
1 and all other seven cell lines are normalized relative to MCF7 mRNA levels. Error bars 
represent SD of 3 experiments, each in triplicate. b) Representative western blotting of KSR1 
expression is shown. Experiments were repeated at least three times. 
 
Figure S4 Validation of KSR1 stable over-expression breast cancer cell line.  MCF7-KSR1 
and MCF7-parental stable cells were generated by transfection of either pCMV6-KSR1 or 
pCMV6-vector into MCF7 cells and selected in the presence of G418 (1 mg/ml). KSR1 
overexpression was confirmed by RT-qPCR and western blotting. Results shown are the 
average of three independent experiments and error bars represent SD of 3 experiments, each 
in triplicate.  
 
Figure S5 SILAC proteomics workflow.  Experimental schematic outline of SILAC 
experiment.  
 
Figure S6 Classification of KSR1-regulated proteins. Distribution of differentially expressed 
proteins (cut-off of log2 ratio >0.5 or <-0.5) after KSR1 overexpression according to their (a) 
biological functions, (b) molecular processes and (c) cellular compartmentalisation (p < 0.005). 
 
Figure S7 Schematic representation of the most significant networks using STRING 
analysis after KSR1 overexpression. Top networks including the most significantly (a) up-
regulated and (b) down-regulated proteins after KSR1 overexpression in MCF7 cells. 
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Figure S8 Neddylation assay of p53 after KSR1 over-expression. MCF7 cells were co-
transfected with HA-NEDD8 and pCMV6 or pCMV6-KSR1 plasmids as indicated. p53 was 
immunoprecipitated using a p53 specific antibody (DO-1) and the neddylated-p53 was detected 
by immunoblotting using anti-NEDD8 and anti-p53 specific antibodies.  
 
Figure S9 Effects of KSR1 over-expression and silencing on either p53 acetylation after 
doxorubicin treatment, and on BRCA1 protein levels in different cancer cell lines. a) 
Effects on acetylated p53 after KSR1 over-expression in response to doxorubicin. MCF7 cells 
were transiently transfected with pCMV6 or pCMV6-KSR1 plasmids for 24 hours, in the 
presence or absence of doxorubicin. p53 acetylation was assessed by immunoblotting with 
specific antibody as indicated. b) Effects of KSR1 over-expression and knock-down on p53 
acetylation in various cancer cell lines. ZR75-1, SKBR3 and HCT116 cells were transiently 
transfected with pCMV6 or pCMV6-KSR1 plasmids for 24 hours, followed by etoposide 
treatment. ZR75-1 cells were transfected with control siRNA (siCT) or siKSR1 for 72 hours 
followed by etoposide treatment. p53 acetylation was assessed by immunoblotting with specific 
antibody as indicated. c) Effects on BRCA1 protein levels after silencing KSR1 in ZR75-1 cells. 
ZR75-1 cells were transfected with control siRNA (siCT) or siKSR1 for 72 hours and western 
blotting was performed to assess the expression of BRCA1 using specific antibody. 
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Materials and methods 
Clinical specimens  
Tissue microarrays (TMAs) containing > 1000 primary operable breast cancer cases from the 
previously validated Nottingham Tenovus Primary Breast Carcinoma Series were employed 3,46-
48. This well-characterized resource contains information on patients’ clinical and pathological 
data including histological tumor type, primary tumor size, lymph node status, histological grade 
and data on other breast cancer relevant biomarkers. These include ERα, PgR, HER2, BRCA1, 
p53, cytokeratins (CKs; 5/6, 7/8, 18), Ki67 and E-cadherin. The immunoreactivity and scoring 
were defined in this series as previously described 49. Patients within the good prognosis group 
(Nottingham Prognostic Index (NPI) ≤ 3.4) did not receive adjuvant therapy. Hormonal therapy 
was prescribed to patients with ERα positive tumors and NPI scores > 3.4 (moderate and poor 
prognostic groups). Pre-menopausal patients within the moderate and poor prognosis groups 
were candidates for chemotherapy. Conversely, postmenopausal patients with moderate or 
poor NPI and ERα positive were offered hormonal therapy, while ERα negative patients 
received chemotherapy. Data collected included overall survival (OS), disease-free survival 
(DFS). Clinical data were maintained on a prospective basis with a median follow-up was 124 
months (range 1 to 233).  
 
Immunohistochenistry 
Anti-KSR1 rabbit polyclonal antibody (Santa Cruz, Heidelberg, Germany) was optimized to a 
working concentration of 2μg on full-face excisional tissue sections. Subsequently, breast 
cancer TMA (n = 945) cases comprising 4Pm thick formalin fixed paraffin embedded tissue 
cores were immuno-stained with anti-KSR1 on the Leica BOND-MAX automated system using 
manufacturer’s instructions. Hit-induced epitope retrieval was performed in citrate buffer (ER1) 
for 5 mins. Detection was achieved using the Polymer Detection kit (Leica Microsystems Inc., 
USA). Determination of the optimal cut-offs were performed using X-tile bioinformatics software 
(Yale University, USA). Cytoplasmic staining was scored based on intensity ranging from 0 to 
+3; 0 = null, +1 = low, +2 = intermediate and +3 = high level of staining intensity. Scoring for 
each tissue core on the TMAs was performed by two independent investigators. High resolution 
digital imaging (NanoZomer, Hamamatsu Photonics, Welwyn Garden City, UK) at 20x 
magnification with a web-based interface (Distiller, SlidePath Ltd., Dublin, Ireland) was used. All 
cases were scored without knowledge of the clinicopathological or outcome data.  
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Protein digestion and peptide fractionation 
Equal amounts of protein from unlabeled and labeled samples were combined prior to protein 
digestion. Briefly, samples were reduced in 10 mM DTT and alkylated in 50 mM Iodoacetamide 
prior to boiling in loading buffer, and then separated by one-dimensional SDS-PAGE (4-12% 
Bis-Tris Novex mini-gel, Invitrogen) and visualized by colloidal  Coomassie staining (Novex, 
Invitrogen). The entire protein gel lanes were excised and cut into 10 slices each. Every gel 
slice was subjected to in-gel digestion with trypsin overnight at 37 oC (Lamond et al., 2011). The 
resulting tryptic peptides were extracted by formic acid (1%) and acetonitile, lyophilized in a 
speedvac and resuspended in 1% formic acid. 
 
Protein digestion and phosphopeptide enrichment 
FASP Procedure was performed as previously described 50. 500 uL FASP 1 (8 M urea, 20 mM 
DDT in 100 mM Tris/HCL pH 8.5 ) was  added to ~2 mg protein lysate to dilute SDS 
concentration and transferred to a Vivacon 500, 30k MWCO HY filter (Sartorius Stedim Biotech, 
VN01H22). The sample was buffer exchanged using FASP1 several times by spinning the tube 
at 7000g to remove detergents. The protein lysate was concentrated by centrifugation and 
diluted in FASP 2 (100 mM Tris/HCl pH 8.5) ready for trypsin digestion. The sample was 
reduced using 50mM fresh IAA in FASP 2 in the dark for 30mins. Lysates were spun down to 
remove excess IAA and buffer exchanged into FASP 3 (100mM TEAB (triethyl ammonium 
bicarbonate)). Trypsin was dissolved in FASP 3 to give a 1:200 enzyme to protein ratio and 
added in a volume of at least 100 PL for 4-6 hours.  This was repeated with fresh trypsin for a 
further overnight incubation. Lysates were spun down and washed with 0.5M NaCl and 150 PL 
10% TFA added to reduce the pH. A standard desalting procedure was used 51. 
Hydrophilic Interaction Chromatography (HILIC) fractionation: A TSKgel Amide-80 separation 
column with a TSKgel Amide guard column was used for HILIC separation of FASP peptides. 
Buffer A: 80 % ACN, 0.1 % Formic Acid & Buffer B: 0.1 % Formic Acid were used for the 
gradient at a flow rate of 0.6 mLs/min. The sample was separated into 45 fractions, collected 
2mins/vial and dried using a speed vac.  
TiO2 Enrichment was performed as previously described 51. TiO2 beads were washed & re-
suspended in Buffer B at 50 ug / uL and added to tubes to give 1 mg per tube. The sample was 
re-suspended in loading buffer, added to beads & incubated at RT for 20 mins. After washes 
using buffers A & B samples were eluted using aliquots of 0.5% NH4OH. Elutions were pooled & 
10 uL of 20 % FA added to adjust the pH. Samples were dried and re-suspended in 1% FA. 
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Mass Spectrometry methods 
Trypsin-digested peptides were separated using an Ultimate 3000 RSLC (Thermo Scientific) 
nanoflow LC system. On average 0.5 µg was loaded with a constant flow of 5 µl/min onto an 
Acclaim PepMap100 nanoViper C18 trap column (100 µm inner-diameter, 2 cm; Themro 
Scientific). After trap enrichment, peptides were eluted onto an Acclaim PepMap RSLC 
nanoViper, C18 column (75 µm, 15 cm; Thermo Scientific) with a linear gradient of 2–40% 
solvent B (80% acetonitrile with 0.08% formic acid) over 65 min with a constant flow of 300 
nl/min. The HPLC system was coupled to a linear ion trap Orbitrap hybrid mass spectrometer 
(LTQ-Orbitrap Velos, Thermo Scientific) via a nano electrospray ion source (Thermo Scientific). 
The spray voltage was set to 1.2 kV, and the temperature of the heated capillary was set to 250 
°C. Full-scan MS survey spectra (m/z 335–1800) in profile mode were acquired in the Orbitrap 
with a resolution of 60,000 after accumulation of 1,000,000 ions. The fifteen most intense 
peptide ions from the preview scan in the Orbitrap were fragmented by collision-induced 
dissociation (normalized collision energy, 35%; activation Q, 0.250; and activation time, 10 ms) 
in the LTQ after the accumulation of 10,000 ions. Maximal filling times were 1,000 ms for the full 
scans and 150 ms for the MS/MS scans. Precursor ion charge state screening was enabled, 
and all unassigned charge states as well as singly charged species were rejected. The lock 
mass option was enabled for survey scans to improve mass accuracy (Olsen, J.V. et al., 2004). 
Data were acquired using the Xcalibur software. 
 
Quantification and bioinformatics analysis 
The raw mass spectrometric data files obtained for each experiment were collated into a single 
quantitated data set using MaxQuant 36 and the Andromeda search engine software 52. Enzyme 
specificity was set to that of trypsin, allowing for cleavage N-terminal to proline residues and 
between aspartic acid and proline residues. Other parameters used were: (i) variable 
modifications, methionine oxidation, protein N-acetylation, gln Æ pyro-glu; (ii) fixed 
modifications, cysteine carbamidomethylation; (iii) database: target-decoy human MaxQuant 
(ipi.HUMAN.v3.68); (iv) heavy labels: R6K4 and R10K8; (v) MS/MS tolerance: FTMS- 10ppm , 
ITMS- 0.6 Da; (vi) maximum peptide length, 6; (vii) maximum missed cleavages, 2; (viii) 
maximum of labeled amino acids, 3; and (ix) false discovery rate, 1%. Peptide ratios were 
calculated for each arginine- and/or lysine-containing peptide as the peak area of labelled 
arginine/lysine divided by the peak area of non-labelled arginine/lysine for each single-scan 
mass spectrum. Peptide ratios for all arginine- and lysine-containing peptides sequenced for 
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each protein were averaged. Data are normalised using 1/median ratio value for each identified 
protein group per labelled sample.  
 
In vivo tumorigenicity assay in breast cancer xenografts in nude mice 
Female 7-week-old, nu/nu-BALB/c athymic nude mice were acclimated in the animal house one 
week before experimentation. Before cells injection, a 0.72mg 17-β Estradiol 60-day release 
pellet was implanted subcutaneously (Innovative Research of America) into each mouse. 5×106 
MCF7-vector or MCF7-KSR1 cells were resuspended in the total volume of 100μL and were 
then injected subcutaneously into the flank of the animals by groups (n=9, per group). Tumor 
growth was analyzed by caliper measurements every three days and calculated using the 
formula 1/2 [length (mm)] x [width (mm)]2. After the mice were sacrificed, primary tumors were 
excised and formalin fixed. Samples were paraffin embedded, cut at 3 μm and IHC stained for 
histological evaluation of target proteins expression. This study was conducted under the UK 
Home Office Project License. 
 
Statistical analysis 
Statistical analysis for TMAs was performed using SPSS 16.0 statistical software (SPSS Inc., 
Chicago, IL, USA). Analysis of categorical variables was performed with the appropriate 
statistical test. Survival curves were analyzed using the Kaplan-Meier method with significance 
determined by the Log rank test; multivariate analysis was performed by Cox hazards 
regression analyses. DFS was defined as the period from the date of initial diagnosis to the date 
of the first documented relapse or death, and OS was defined as the time from the initial 
diagnosis to death. DFS time was censored at the date of last follow-up if patients were still 
relapse-free and alive, and OS was censored at the time when patients were alive. A forward 
stepwise Cox regression model was conducted to select baseline patient demographic and 
tumor characteristics to be included in the multivariate analyses of 2 KSR1 polymorphisms and 
clinical outcome. Chi-square tests were used to examine the associations between tumor 
characteristics and KSR1 polymorphisms. Tests were 2-sided at a 0.05 significance level. 
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Supplementary Materials and methods 
 
Cell lines, reagents, antibodies and plasmids 
MCF7, BT474, T47D, ZR75-1, MDA231, MDA468 and SKBR3 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal calf serum (FCS) 
and 1% penicillin (P) / streptomycin (S) / glutamine (G). MLET5 cell line was grown in phenol 
red free DMEM supplemented with 10% DSS and 1% P/S/G. All cells were incubated at 37 °C 
in humidified 5% CO2. FuGENE® HD transfection reagent was obtained from Roche (Burgess 
Hill, UK). Etoposide was purchased from Sigma Aldrich. The Dual-Glo™ Luciferase Assay 
System was purchased from Promega (Southampton, UK). The following antibodies have been 
used: KSR1 rabbit polyclonal (Santa Cruz and Cell Signaling), Anti-Flag mouse monoclonal 
(Sigma Aldrich), p53 mouse monoclonal DO-1 (Santa Cruz), Acetylated-p53 and phospho-p53 
Ser15 rabbit polyclonal (Cell Signaling), BRCA1 rabbit polyclonal (Santa Cruz), BARD1 rabbit 
polyclonal (Cell Signaling), SIRT1 rabbit polyclonal (Santa Cruz), DBC1 and phospho-DBC1 
Thr454 rabbit polyclonal (Cell Signaling), Ubiquitin mouse monoclonal (Cell Signaling) and β-
actin mouse monoclonal (Abcam). The following p53-target gene promoter-reporter constructs 
previously described 53, were a kind gift from Prof. Kanaga Sabapathy: AIP-1-luciferase (luc), 
IGFBP3-luc, R2-luc and cyclinG1-luc. The renilla luciferase reporter vector (pRL-TK) was 
purchased from Promega (Southampton, UK).  
 
Protein extraction and western blotting 
NP40 lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10%(v/v) glycerol, 1% NP40, 5 mM 
dithiothreitol (DTT), 1 mM EDTA, 1 mM EGTA, 50 μM leupeptin and 30 μg/ml aprotinin) was 
used to extract whole cell lysates. Cell pallets were mixed thoroughly with NP40 lysis buffer, and 
then incubated in ice for 15 min before centrifuging at 15000 rpm for 15 min at 4 °C. Nuclear 
and cytoplasmic extracts were prepared from whole-cell lysis using NE-PER Nuclear and 
Cytoplasmic Extraction Kit (Thermo Scientific). Protein concentration was measured by the 
bicinchoninic acid (BCA) protein assay (Pierce). Lysates were heated with 5x sodium dodecyl 
sulfates (SDS) sample buffer at 95 °C for 5 min before they were loaded to 10% SDS-PAGE. 
Samples were then transferred to Hybond ECL super nitrocellulose membranes (GE 
Healthcare). Subsequently the membranes were blocked in TBS containing 0.1% (v/v) Tween20 
and 5% (w/v) non-fat milk for 1 h. The primary antibodies were probed with membranes 
overnight at 4 °C. The membranes were then washed three times in TBS/Tween for 15 min 
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following incubation with HRP-conjugated secondary antibodies (1:3000 dilution) for 60 min. 
The membranes were then washed three times again and were detected with Enhanced 
chemiluminescence (ECL). Films were developed using a Konica SRX-1001A X-ray developer. 
Alternatively, membranes were incubated with IRDye® Donkey anti-mouse or Donkey anti-rabbit 
secondary antibodies for 60 min and visualized by Odyssey® Fc Imaging System (LI-COR®). 
 
RNA extraction and RT-qPCR 
RNeasy kit (Qiagen) was used to isolate total RNA. Reverse transcription was performed using 
high capacity cDNA reverse transcription kit (Applied Biosystems). RT-qPCR analysis was 
performed on a 7900HT Thermocycler (Applied Biosystems) using TaqMan mastermix and 
primers for TP53, p21, KSR1, BRCA1 and GAPDH cDNAs, purchased from Applied 
Biosystems. 
 
siRNA knock-down, constructs and generation of KSR1 stable cell lines 
siKSR1 were purchased from Qiagen and verified. Plasmids containing human wild type KSR1 
(pCMV6-KSR1) and empty vector (pCMV6-vector) were obtained from OriGene. MCF7-parental 
and MCF7-KSR1 stable cells were generated by transfection of either pCMV6-vector or pCMV6-
KSR1 in MCF7 cells and selected in the presence of G418 (1 mg/ml). KSR1 overexpression 
was confirmed by RT-qPCR and western blotting.  
 
Luciferase reporter assay 
8×104/well MCF7 cells were seeded into 24-well plate and transfection was performed using 
FuGENE® HD transfection reagent according to manufacturer’s instructions (Roche, UK). Cells 
were transfected with different p53 constructs, and pCMV6-KSR1 or pCMV6-vector and 
together with renilla luciferase reporter vector (pRL-TK). Cell lysates were collected after 24 
hours transfection and firefly and renilla luciferase activities were measured by the Dual-Glo™ 
Luciferase Assay kit as manufacturer’s protocols described. The transcriptional activity of 
various p53 constructs were determined by firefly luciferase activity and normalized against 
renilla luciferase activity which was served as control for transfection efficiency.  
 
Three-dimensional overlay culture in Matrigel 
Matrigel (BD Biosciences) was thawed on ice overnight at 4 ºC and 70 μl was added into each 
of the wells of the eight-well glass slide chambers (Thermo Scientific), and spread evenly in the 
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well to form a 1 mm thick bed. Matrigel was left to solidify at 37 ºC for 15 min. Next, cells (5 x 
103/well) were plated in medium containing 2% Matrigel and allowed to grow in a 5% CO2 
humidified incubator at 37 ºC for 10 days. The assay medium containing 2% Matrigel was 
replaced every 4 days. Axiovert 100 MetaMorph microscope was used to image colonies in 
Matrigel.  
 
Soft agar assay 
Cells were plated in 0.3% agar on top of 0.6% agar in six-well plate in triplicates. Every 4 days, 
full DMEM medium with G418 (500 µg/ml) was replenished on the top layer. After incubation for 
2 weeks, colonies were counted in 3 random fields per well and photographed. 
Single nucleotide polymorphisms and genotyping 
In those patients for whom adequate tissue was available, candidate KSR1 polymorphisms 
were chosen with the assistance of the Ensembl program using two main criteria: first, that the 
polymorphism has some degree of likelihood to alter the function of the gene in a biological 
relevant manner. Intronic or exonic polymorphisms can change gene transcription levels by 
alternative splicing or by affecting binding of a transcription factor. Second, that the frequency of 
the polymorphism is sufficient enough that its impact in clinical outcome would be meaningful on 
a population level (> 10% allele frequency). Genomic DNA was extracted from micro-dissected 
tissue specimens using the QIAamp kit (Qiagen). Two KSR1 polymorphisms (rs2241906 and 
rs1075952) were tested using polymerase chain reaction restriction fragment length 
polymorphism (PCR-RFLP) technique. 
 
SILAC cell culture 
SILAC dialysed calf serum and custom DMEM mediums containing either unlabelled [12C6,14N4]-
arginine (Arg) and [12C6]-lysine (Lys) (R0K0 -‘light’) or labelled [13C6,15N4]-Arg and [13C6]-Lys 
(R10K8 -‘heavy’) were purchased from Dundee cell products (Dundee, UK)  MCF7 cells were 
grown in these custom DMEM mediums along with 10% dialysed FCS and 1% of antibiotics 
(Penicillin and Streptomycin). The cells that were grown for at least seven passages were used 
for this experiment.   
 
Neddylation assay 
MCF7 cells plated on 15 cm dishes were transfected using FuGENE® HD with 8 µg pcDNA3-
HA-NEDD8 (Addgene), 8 µg pCMV6-KSR1 or 8 µg pCMV6-Vector constructs as indicated.  
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After 24 hours, cells were lysed in Radio-Immunoprecipitation Assay (RIPA) buffer (Sigma 
Aldrich) supplemented with protease inhibitors. Total protein was quantified by the BCA assay 
(Pierce). 2 µg Mouse IgG or p53 (DO-1) was pre-incubated with protein agarose beads for 2 
hours to form IP matrix complex (ImmunoCruz™ IP/WB Optima C System, Santa Cruz). 2 mg 
protein lysate was added into the beads and was incubated on a rotator overnight at 4 °C. 
Beads were washed with RIPA buffer for three times and were heated in SDS loading buffer. 
Neddylated p53 were detected by western blot using p53-specific DO-1 antibody or NEDD8 
antibody (Cell Signalling) as described before37,38. 
 
Ubiquitination assay 
MCF7 cells were transfected with pCMV6-KSR1 or pCMV6-Vector constructs using FuGENE® 
HD.  After 24 hours, cells were lysed and total protein was quantified. Rabbit IgG or BRCA1 
antibody was pre-incubated with protein agarose beads for 2 hours to form IP matrix complex 
(ImmunoCruz™ IP/WB Optima B System, Santa Cruz). 2 mg protein lysate was added into the 
beads and was incubated on a rotator overnight at 4 °C. Beads were then washed with RIPA 
buffer for three times and were heated in SDS loading buffer. Endogenous ubiquitinated BRCA1 
was detected using anti-ubiquitin antibody by western blot. 
Immunofluorescence staining 
MCF7 cells seeded on glass coverslips in 6 cm dishes were transfected with pCMV6-KSR1 or 
pCMV6-Vector using FuGENE® HD. Cells were fixed in 4% w/v paraformaldehyde at 37 °C for 
15 min, permeabilized with 0.1% Triton-X for 10 min and incubated in immune-fluorescent 
blocking buffer (10% AB-serum in PBS) for 1h, followed by incubation with p53 antibody (DO-1). 
After washing with PBS, coverslips were incubated for 45 min at 37 °C with anti-mouse-IgG 
Alexa Fluor® -555 antibody (Invitrogen). DNA was visualized by DAPI staining. Cells were 
examined on an Axiovert-200 laser scanning inverted microscope (Zeiss) as previously 
described 3.  
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Table 1. Patients’ characteristics and tumor biomarkers and correlations with KSR1 
expression in European breast cancer patients. 
 
 
 
  
 
Variable/biomarker 
KSR1 expression P value 
Weak (%) Strong (%)  
Tumor Stage    
1 370(59.7) 191(58.2) 0.787 
2 194(31.3) 103(31.4)  
3 56(9.0) 34(10.4)  
Grade    
1 95(15.3) 42(12.8) 0.544 
2 199(32.0) 104(31.7)  
3 328(52.7) 182(55.5)  
Tumor Size    
<1.5cm 141(22.7) 71(21.6) 0.719 
=>1.5cm 481(77.3) 257(78.4)  
Age 
<50 
=>50 
Vascular Invasion 
 
197(31.6) 
427(68.4) 
 
120(36.6) 
208(63.4) 
 
0.119 
 
 
Definitive 217(34.9) 115(35.6) 0.973 
Negative 326(52.4) 168(52.0)  
Probable 79(12.7) 40(12.4)  
Tumor type    
Invasive Ductal 376(61.3) 215(67.0) 0.180 
Other 237(38.7) 106(33.1)  
ER Status    
Negative 167(27.5) 103(32.2) 0.149 
Positive 440(72.5) 217(67.7)  
PgR Status    
Negative 258(43.1) 144(45.9) 0.420 
Positive 341(56.9) 170(54.1)  
HER2 Status    
Negative 521(85.4) 273(84.3) 0.639 
Positive 89(14.6) 51(15.7)  
Triple Negative Status    
Non-Triple 493(81.9) 249(77.8) 0.137 
Triple Negative  109(18.1) 71(22.2)  
Cytokeratin 5/6    
Negative 504(83.3) 260(81.8) 0.555 
Positive 101(16.7) 58(18.2)  
Cytokeratin 14    
Negative 522(86.4) 273(86.7) 0.919 
Positive 82(13.6) 42(13.3)  
BRCA1    
0 100(20.0) 40(15.2) 0.002 
1 222(44.4) 96(36.4)  
2 178(35.6) 128(48.5)  
P53    
0 332(69.7) 200(76.9) 0.038 
1 144(30.3) 60(23.1)  
Ki67    
0 175(42.0) 79(36.1) 0.149 
1 242(58.0) 140(63.9)  
 
Table 2. Cox-proportional hazards analysis for predictors (model including KSR1 
expression) of overall survival (OS) and disease-free survival (DFS) 
 
 
a Fitted as linear term, i.e., Increase in risk for change in lymph node stage of one unit  
b Fitted as linear term, i.e., Increase in risk for change in grade of one unit  
c Compared with tumour size ≤1.5cm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
 
OS 
   
DFS 
 
Hazard 
ratio 
 
95% CI 
 
P  value 
  
Hazard 
ratio 
 
95% CI 
  
P  value 
           
Stagea 1.846 1.562-2.180 <0.001  
 
   1.893  1.585-2.260  <0.001 
Gradeb 1.755 1.435-2.146 <0.001  
 
   2.222  1.747-2.825  <0.001 
Size>1.5 cmc 1.825 1.246-2.674  0.002     2.026  1.310-3.134 0.002 
 
0.002 
        
KSR1 status 1.543 1.189-2.001  0.001     1.541  1.166-2.037 
Supplementary Table 1. SILAC KSR1-upregulated proteins (- log2 >0.5 fold).  
Protein IDs Protein Descriptions Normalised 
R10K8/R0K0 
Log2 
R10K8/R0K0 
IPI00651657 Isoform 1 of Kinase suppressor of Ras 1 4.3486 2.1205 
IPI00012912 Carnitine O-palmitoyltransferase 2, mitochondrial 4.3074 2.1068 
IPI00030781 Isoform Alpha of Signal transducer and activator of transcription 1-alpha/beta 2.5401 1.3450 
IPI00002606 Isoform 1 of Adseverin 1.8201 0.8640 
IPI00296922 Laminin subunit beta-2 1.7680 0.8221 
IPI00748360 Uncharacterized protein KIAA1797 1.7324 0.7928 
IPI00220007 cDNA FLJ55764, highly similar to Apolipoprotein-L2 1.6657 0.7361 
IPI00028376 Mitochondrial import inner membrane translocase subunit Tim8 A 1.6590 0.7304 
IPI00011200 D-3-phosphoglycerate dehydrogenase 1.6582 0.7297 
IPI00027745 Isoform Long of Beta-glucuronidase 1.6364 0.7105 
IPI00000663 Isoform Mitochondrial of Malonyl-CoA decarboxylase, mitochondrial 1.6268 0.7021 
IPI00549664 Testis-expressed sequence 10 protein 1.6001 0.6782 
IPI00027741 Isoform 1 of NF-kappa-B inhibitor zeta 1.5888 0.6680 
IPI00304082 Isochorismatase domain-containing protein 1 1.5729 0.6534 
IPI00183110 Isoform 1 of Paternally-expressed gene 3 protein 1.5601 0.6416 
IPI00428967 TRAM adaptor with GOLD domain isoform 1 1.5321 0.6155 
IPI00297910 Tumor-associated calcium signal transducer 2 1.5232 0.6071 
IPI00789848 isovaleryl Coenzyme A dehydrogenase isoform 1 1.5144 0.5988 
IPI00797038 mitochondrial phosphoenolpyruvate carboxykinase 2 isoform 1 precursor 1.5086 0.5932 
IPI00303726 Interferon-induced transmembrane protein 3 1.5076 0.5923 
IPI00550020 Parathymosin 1.4883 0.5737 
IPI00386227 cDNA: FLJ21617 fis, clone COL07481 1.4746 0.5603 
IPI00020632 Argininosuccinate synthase 1.4657 0.5516 
IPI00219930 Cellular retinoic acid-binding protein 1 1.4642 0.5501 
IPI00219038 Histone H3.3 1.4490 0.5351 
IPI00002459 annexin VI isoform 2 1.4483 0.5344 
IPI00657752 Putative uncharacterized protein CD81 1.4418 0.5279 
IPI00795107 Similar to Deoxyribonuclease 1.4324 0.5185 
IPI00294065 Isoform 1 of Golgin subfamily A member 5 1.4277 0.5137 
IPI00026496 Nucleoplasmin-3 1.4238 0.5098 
IPI00009659 Regulation of nuclear pre-mRNA domain-containing protein 1B 1.4051 0.4907 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2. SILAC KSR1-downregulated proteins (- log2 <0.5 fold). 
Protein IDs Protein Descriptions Normalised 
R10K8/R0K0 
Log2  
R10K8/R0K0 
IPI00027505 Isoform 1 of Integrin alpha-V 0.0237 -5.4019 
IPI00913961 18 kDa protein 0.0550 -4.1856 
IPI00789159 Ribosomal protein L23a, isoform CRA_a 0.0984 -3.3446 
IPI00453473 Histone H4 0.1158 -3.1097 
IPI00418471 Vimentin 0.1647 -2.6024 
IPI00018300 Interferon-induced protein with tetratricopeptide repeats 1 0.1973 -2.3413 
IPI00221089 40S ribosomal protein S13 0.2779 -1.8471 
IPI00216219 Isoform Long of Tight junction protein ZO-1 0.2821 -1.8256 
IPI00651622 2-5 oligoadenylate synthetase 1 p52 isoform 0.2880 -1.7956 
IPI00015141 Creatine kinase S-type, mitochondrial 0.3200 -1.6441 
IPI00657888 Isoform 2 of Mannose-1-phosphate guanyltransferase alpha 0.3699 -1.4349 
IPI00878252 Isoform 1 of General transcription factor 3C polypeptide 2 0.3738 -1.4197 
IPI00291764 Histone H2A type 1 0.3873 -1.3684 
IPI00935700 Isoform 13 of Synaptotagmin-like protein 2 0.4207 -1.2493 
IPI00743871 Isoform 1 of Integrator complex subunit 7 0.4213 -1.2471 
IPI00000425 V-type proton ATPase 116 kDa subunit a isoform 2 0.4215 -1.2464 
IPI00002441 Syndecan-1 0.4355 -1.1992 
IPI00299387 Transmembrane protein C3orf1 0.4518 -1.1462 
IPI00060521 FLYWCH family member 2 0.4950 -1.0145 
IPI00719178 Isoform 9 of Multidrug resistance-associated protein 1 0.5023 -0.9934 
IPI00306127 THUMP domain-containing protein 3 0.5163 -0.9539 
IPI00470883 stromal antigen 2 isoform a 0.5190 -0.9461 
IPI00006608 Isoform APP770 of Amyloid beta A4 protein (Fragment) 0.5199 -0.9436 
IPI00654731 Isoform 1 of Probable ATP-dependent RNA helicase DDX58 0.5250 -0.9297 
IPI00022649 Isoform 1 of Solute carrier family 12 member 2 0.5370 -0.8971 
IPI00103884 Ovarian cancer-associated gene 2 protein 0.5401 -0.8888 
IPI00249304 
Isoform 1 of Peroxisomal proliferator-activated receptor A-interacting complex 
285 kDa protein 0.5465 -0.8717 
IPI00514897 Brefeldin A-inhibited guanine nucleotide-exchange protein 3 0.5484 -0.8668 
IPI00247871 Isoform 1 of Transcription elongation regulator 1 0.5502 -0.8621 
IPI00167949 Interferon-induced GTP-binding protein Mx1 0.5522 -0.8567 
IPI00873607 Isoform 1 of Thioredoxin-related transmembrane protein 2 0.5548 -0.8499 
IPI00219871 U6 snRNA-associated Sm-like protein LSm8 0.5549 -0.8497 
IPI00106687 Latexin 0.5613 -0.8331 
IPI00294834 Aspartyl/asparaginyl beta-hydroxylase 0.5736 -0.8019 
IPI00791049 HLA-B associated transcript 5, isoform CRA_b 0.5743 -0.8000 
IPI00179473 Isoform 1 of Sequestosome-1 0.5805 -0.7846 
IPI00293533 Nuclear pore glycoprotein p62 0.5817 -0.7815 
IPI00184772 Putative uncharacterized protein DOCK6 0.5832 -0.7780 
IPI00298793 Beta-mannosidase 0.5837 -0.7768 
IPI00012545 Isoform TGN51 of Trans-Golgi network integral membrane protein 2 0.5873 -0.7679 
IPI00061108 Isoform 1 of Ribosome-recycling factor, mitochondrial 0.5889 -0.7638 
IPI00853099 Isoform 2 of Zinc finger transcription factor Trps1 0.5965 -0.7454 
IPI00003818 Kynureninase 0.5967 -0.7450 
IPI00004312 Isoform Long of Signal transducer and activator of transcription 2 0.5983 -0.7411 
IPI00419979 p21 protein (Cdc42/Rac)-activated kinase 2 0.5987 -0.7400 
IPI00008711 Wolframin 0.6001 -0.7366 
IPI00409659 Ubiquilin-2 0.6039 -0.7277 
IPI00305010 Isoform 1 of Calcineurin-like phosphoesterase domain-containing protein 1 0.6051 -0.7247 
IPI00375631 Interferon-induced 17 kDa protein 0.6059 -0.7229 
IPI00941977 ZYX protein (Fragment) 0.6103 -0.7123 
IPI00005260 Isoform 1 of Proteasome activator complex subunit 4 0.6105 -0.7119 
IPI00010187 Elongation of very long chain fatty acids protein 1 0.6110 -0.7108 
IPI00009896 Epoxide hydrolase 1 0.6177 -0.6950 
IPI00009982 Isoform 1 of Tudor and KH domain-containing protein 0.6180 -0.6944 
IPI00013735 Isoform 1 of FAST kinase domain-containing protein 2 0.6197 -0.6903 
IPI00100796 Charged multivesicular body protein 5 0.6217 -0.6856 
IPI00002188 Brefeldin A-inhibited guanine nucleotide-exchange protein 1 0.6220 -0.6850 
IPI00924788 arylacetamide deacetylase-like 1 isoform a 0.6273 -0.6727 
IPI00647491 Isoform 1 of Mitochondrial ribonuclease P protein 3 0.6291 -0.6686 
IPI00296907 Isoform 1 of Peroxisomal acyl-coenzyme A oxidase 1 0.6310 -0.6643 
IPI00329572 Protein kinase C and casein kinase substrate in neurons protein 3 0.6326 -0.6606 
IPI00215780 40S ribosomal protein S19 0.6346 -0.6562 
IPI00296635 1,4-alpha-glucan-branching enzyme 0.6355 -0.6540 
IPI00104050 Thyroid hormone receptor-associated protein 3 0.6381 -0.6481 
IPI00414384 Isoform 1 of Hydroxysteroid dehydrogenase-like protein 2 0.6395 -0.6449 
IPI00010207 Ubiquitin-fold modifier 1 0.6435 -0.6360 
IPI00010400 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-3 0.6441 -0.6346 
IPI00023556 
Isoform 1 of RNA polymerase II subunit A C-terminal domain phosphatase 
SSU72 0.6447 -0.6333 
IPI00260715 Fus-like protein (Fragment) 0.6463 -0.6297 
IPI00291783 Gem-associated protein 5 0.6479 -0.6261 
IPI00334282 Protein FAM3C 0.6489 -0.6238 
IPI00307257 Isoform 1 of TBC1 domain family member 9B 0.6503 -0.6208 
IPI00291215 poly (ADP-ribose) polymerase family, member 14 0.6529 -0.6151 
IPI00009225 Syntaxin-8 0.6529 -0.6150 
IPI00102864 Hexokinase-2 0.6530 -0.6149 
IPI00030098 Protein FAM50A 0.6556 -0.6091 
IPI00470631 Isoform 1 of Ubiquinone biosynthesis protein COQ9, mitochondrial 0.6571 -0.6058 
IPI00010440 Isoform 1 of HCLS1-associated protein X-1 0.6590 -0.6016 
IPI00013930 Syntaxin-6 0.6605 -0.5984 
IPI00220271 Alcohol dehydrogenase [NADP+] 0.6608 -0.5977 
IPI00020719 Isoform 1 of Mitochondrial antiviral-signaling protein 0.6618 -0.5956 
IPI00304163 C12orf10 protein 0.6618 -0.5955 
IPI00337386 Isoform 2 of Pre-mRNA-processing factor 40 homolog A 0.6649 -0.5889 
IPI00008986 Large neutral amino acids transporter small subunit 1 0.6681 -0.5819 
IPI00398922 Protein phosphatase 1 regulatory subunit 14B 0.6695 -0.5789 
IPI00030774 Isoform 4 of Tubulin-specific chaperone D 0.6709 -0.5758 
IPI00152441 Isoform 1 of Minor histocompatibility antigen H13 0.6714 -0.5748 
IPI00329410 Dolichyldiphosphatase 1 0.6735 -0.5703 
IPI00307409 39S ribosomal protein L9, mitochondrial 0.6765 -0.5639 
IPI00065063 Dehydrogenase/reductase SDR family member 1 0.6773 -0.5622 
IPI00218163 Isoform 2 of Mucin-1 0.6783 -0.5599 
IPI00025086 Cytochrome c oxidase subunit 5A, mitochondrial 0.6814 -0.5534 
IPI00328911 E3 ubiquitin-protein ligase HECTD1 0.6817 -0.5528 
IPI00306604 Integrin alpha-5 0.6824 -0.5512 
IPI00012462 Eukaryotic translation initiation factor 2A 0.6908 -0.5337 
IPI00329692 Isoform Long of Glycylpeptide N-tetradecanoyltransferase 1 0.6927 -0.5297 
IPI00103654 Isoform 1 of Serine/threonine-protein phosphatase 4 regulatory subunit 2 0.6934 -0.5282 
IPI00478657 G-rich sequence factor 1 0.6937 -0.5277 
IPI00014311 cDNA FLJ56037, highly similar to Cullin-2 0.6939 -0.5272 
IPI00219729 Mitochondrial 2-oxoglutarate/malate carrier protein 0.6958 -0.5232 
IPI00003843 cDNA FLJ53324, highly similar to Tight junction protein ZO-2 0.6963 -0.5223 
IPI00169342 Isoform 1 of RNA-binding protein 47 0.6971 -0.5206 
IPI00926109 Isoform 2 of Putative ATP-dependent RNA helicase DHX30 0.6999 -0.5148 
IPI00253036 Isoform I of CD99 antigen 0.7032 -0.5081 
IPI00014068 Isoform 1 of Serine/threonine-protein kinase PAK 4 0.7051 -0.5042 
IPI00910694 
cDNA FLJ58598, highly similar to Homo sapiens NOL1/NOP2/Sun domain 
family, member 5 (NSUN5), transcript variant 1, mRNA 0.7054 -0.5035 
IPI00873518 MAD1 mitotic arrest deficient-like 1 0.7054 -0.5035 
IPI00016613 CSNK2A1 protein 0.7065 -0.5012 
IPI00024976 Mitochondrial import receptor subunit TOM22 homolog 0.7070 -0.5003 
 
 
 
 
 
 
 
Supplementary Table 3. Significance B test of KSR1 regulated proteins (SILAC data). 
Protein IDs Protein Descriptions Log2 Ratio  
R10K8/R0K0 
Log2 Ratio Sign B 
R10K8/R0K0 
IPI00027505 Isoform 1 of Integrin alpha-V -5.4019 0 
IPI00789159 Ribosomal protein L23a, isoform CRA_a -3.3446 1.37E-137 
IPI00913961 18 kDa protein -4.1856 5.36E-136 
IPI00453473 Histone H4 -3.1097 1.72E-119 
IPI00221089 40S ribosomal protein S13 -1.8471 2.56E-44 
IPI00651622 2-5 oligoadenylate synthetase 1 p52 isoform -1.7956 1.28E-26 
IPI00291764 Histone H2A type 1 -1.3684 1.50E-25 
IPI00651657 Isoform 1 of Kinase suppressor of Ras 1 2.1205 2.43E-15 
IPI00012912 Carnitine O-palmitoyltransferase 2, mitochondrial 2.1068 3.60E-15 
IPI00418471 Vimentin -2.6024 2.37E-11 
IPI00018300 Interferon-induced protein with tetratricopeptide repeats 1 -2.3413 2.17E-09 
IPI00654731 Isoform 1 of Probable ATP-dependent RNA helicase DDX58 -0.9297 2.78E-08 
IPI00022649 Isoform 1 of Solute carrier family 12 member 2 -0.8971 8.22E-08 
IPI00215780 40S ribosomal protein S19 -0.6562 1.84E-07 
IPI00030781 Isoform Alpha of Signal transducer and activator of transcription 1-alpha/beta 1.345 2.57E-07 
IPI00167949 Interferon-induced GTP-binding protein Mx1 -0.8567 3.01E-07 
IPI00106687 Latexin -0.8331 6.25E-07 
IPI00002441 Syndecan-1 -1.1992 1.00E-06 
IPI00002606 Isoform 1 of Adseverin 0.864 1.02E-06 
IPI00216219 Isoform Long of Tight junction protein ZO-1 -1.8256 4.08E-06 
IPI00419979 p21 protein (Cdc42/Rac)-activated kinase 2 -0.74 9.31E-06 
IPI00375631 Interferon-induced 17 kDa protein -0.7229 1.48E-05 
IPI00011200 D-3-phosphoglycerate dehydrogenase 0.7297 3.31E-05 
IPI00015141 Creatine kinase S-type, mitochondrial -1.6441 3.75E-05 
IPI00787853 Inositol monophosphatase 3 -0.4843 7.77E-05 
IPI00008454 DnaJ homolog subfamily B member 11 -0.4786 9.24E-05 
IPI00260715 Fus-like protein (Fragment) -0.6297 0.000156903 
IPI00011229 Cathepsin D -0.454 0.000192336 
IPI00304082 Isochorismatase domain-containing protein 1 0.6534 0.000229765 
IPI00215637 ATP-dependent RNA helicase DDX3X -0.4458 0.000243857 
IPI00183110 Isoform 1 of Paternally-expressed gene 3 protein 0.6416 0.000305972 
IPI00657888 Isoform 2 of Mannose-1-phosphate guanyltransferase alpha -1.4349 0.000365313 
IPI00878252 Isoform 1 of General transcription factor 3C polypeptide 2 -1.4197 0.000426105 
IPI00008986 Large neutral amino acids transporter small subunit 1 -0.5819 0.000470449 
IPI00297910 Tumor-associated calcium signal transducer 2 0.6071 0.000628294 
IPI00554481 Isoform 4 of 4F2 cell-surface antigen heavy chain -0.4038 0.000779341 
IPI00025086 Cytochrome c oxidase subunit 5A, mitochondrial -0.5534 0.000873456 
IPI00797038 mitochondrial phosphoenolpyruvate carboxykinase 2 isoform 1 precursor 0.5932 0.00092276 
 
 
Supplementary Table 4. SILAC KSR1-upregulated phosphorylated proteins (– log2 >0.15 
fold). 
Protein IDs Protein Descriptions Normalised 
R10K8/R0K0 
Log2 
R10K8/R0K0 
IPI00418169 Isoform 2 of Annexin A2 2.933 1.552 
IPI00376756 similar to high mobility group box 3 1.886 0.916 
IPI00152409 Anterior gradient protein 3 homolog 1.616 0.692 
IPI00021405 Isoform A of Lamin-A/C 1.454 0.540 
IPI00900293 filamin B isoform 1 1.452 0.538 
IPI00554788 Keratin, type I cytoskeletal 18 1.450 0.536 
IPI00026530 Protein ERGIC-53 1.435 0.521 
IPI00216319 14-3-3 protein eta 1.434 0.520 
IPI00013214 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae), isoform CRA_b 1.426 0.512 
IPI00026215 Flap endonuclease 1 1.421 0.507 
IPI00473136 Isoform 2 of Catenin alpha-1 1.410 0.496 
IPI00394926 DNA polymerase delta subunit 3 1.387 0.472 
IPI00657752 Putative uncharacterized protein CD81 1.376 0.461 
IPI00017451 Splicing factor 3 subunit 1 1.369 0.453 
IPI00843975 Ezrin 1.356 0.440 
IPI00164672 Putative uncharacterized protein DCP1A 1.353 0.436 
IPI00470502 Isoform 2 of Inorganic pyrophosphatase 2, mitochondrial 1.344 0.426 
IPI00019502 Isoform 1 of Myosin-9 1.306 0.385 
IPI00020017 Adipose most abundant gene transcript 2 protein 1.300 0.378 
IPI00217405 Isoform 1 of E3 ubiquitin-protein ligase UBR1 1.292 0.370 
IPI00883857 Isoform Long of Heterogeneous nuclear ribonucleoprotein U 1.282 0.358 
IPI00299507 Condensin complex subunit 2 1.270 0.344 
IPI00886784 similar to hCG1991922 1.268 0.343 
IPI00746934 Isoform 2 of E3 ubiquitin-protein ligase UBR4 1.265 0.340 
IPI00294426 Isoform Long of TATA-binding protein-associated factor 2N 1.265 0.339 
IPI00303439 cDNA FLJ13963 fis, clone Y79AA1001299, highly similar to Homo sapiens 
integrase interactor 1b protein 
1.265 0.339 
IPI00021812 Neuroblast differentiation-associated protein AHNAK 1.260 0.334 
IPI00019329 Dynein light chain 1, cytoplasmic 1.259 0.332 
IPI00015029 Prostaglandin E synthase 3 1.256 0.329 
IPI00294065 Isoform 1 of Golgin subfamily A member 5 1.255 0.328 
IPI00872028 NUMA1 variant protein (Fragment) 1.254 0.327 
IPI00062037 Dynein light chain 2, cytoplasmic 1.252 0.324 
IPI00004860 Isoform Complexed of Arginyl-tRNA synthetase, cytoplasmic 1.247 0.318 
IPI00465248 Isoform alpha-enolase of Alpha-enolase 1.246 0.318 
IPI00022002 cDNA FLJ54536, highly similar to Mitochondrial 28S ribosomal protein S27 1.246 0.317 
IPI00069084 Isoform 1 of Transformation/transcription domain-associated protein 1.240 0.310 
IPI00643591 cDNA FLJ46199 fis, clone TESTI4007965, highly similar to AP-1 complex subunit 
gamma-1 
1.235 0.304 
IPI00033130 SUMO-activating enzyme subunit 1 1.229 0.297 
IPI00027834 Heterogeneous nuclear ribonucleoprotein L 1.227 0.295 
IPI00852968 SNARE Vti1a-beta protein 1.216 0.282 
IPI00844578 ATP-dependent RNA helicase A 1.213 0.278 
IPI00001159 Translational activator GCN1 1.210 0.275 
IPI00385652 Isoform 1 of Serine/threonine-protein kinase tousled-like 2 1.206 0.270 
IPI00007074 Tyrosyl-tRNA synthetase, cytoplasmic 1.202 0.265 
IPI00032780 Intersex-like 1.200 0.263 
IPI00009342 Ras GTPase-activating-like protein IQGAP1 1.198 0.261 
IPI00018349 DNA replication licensing factor MCM4 1.196 0.258 
IPI00007928 Pre-mRNA-processing-splicing factor 8 1.195 0.256 
IPI00021263 14-3-3 protein zeta/delta 1.193 0.255 
IPI00013933 Isoform DPI of Desmoplakin 1.191 0.252 
IPI00008274 Isoform 1 of Adenylyl cyclase-associated protein 1 1.190 0.251 
IPI00607584 Isoform 2 of Myb-binding protein 1A 1.185 0.245 
IPI00031627 DNA-directed RNA polymerase II subunit RPB1 1.183 0.243 
IPI00165230 Isoform 1 of DAZ-associated protein 1 1.183 0.242 
IPI00072534 Isoform 1 of Protein unc-45 homolog A 1.183 0.242 
IPI00884061 hypothetical protein LOC552889 1.182 0.242 
IPI00235412 cDNA FLJ56381, highly similar to Dynamin-1-like protein 1.181 0.240 
IPI00414717 Isoform 2 of Golgi apparatus protein 1 1.177 0.235 
IPI00007021 Mediator of RNA polymerase II transcription subunit 31 1.174 0.232 
IPI00096066 Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial 1.174 0.231 
IPI00289819 Cation-independent mannose-6-phosphate receptor 1.169 0.225 
IPI00021440 Actin, cytoplasmic 2 1.168 0.224 
IPI00942520 cDNA FLJ55610, highly similar to Protein arginine N-methyltransferase 1 1.166 0.222 
IPI00419249 Isoform 1 of Proteasome subunit alpha type-3 1.166 0.222 
IPI00000816 14-3-3 protein epsilon 1.160 0.215 
IPI00024368 Isoform Long of Probable phospholipid-transporting ATPase IIA 1.155 0.208 
IPI00394668 Isoform 4 of Double-stranded RNA-specific adenosine deaminase 1.151 0.203 
IPI00409684 Isoform 2 of Nck-associated protein 1 1.150 0.201 
IPI00215637 ATP-dependent RNA helicase DDX3X 1.146 0.197 
IPI00101374 cDNA FLJ61658, highly similar to Transmembrane 9 superfamily protein member 
1 
1.146 0.197 
IPI00929344 phosphoribosylformylglycinamidine synthase 1.145 0.196 
IPI00306400 Kinesin-like protein KIFC1 1.145 0.195 
IPI00307155 Rho-associated protein kinase 2 1.145 0.195 
IPI00018098 Isoform 1 of Pre-mRNA-splicing factor 38B 1.142 0.192 
IPI00916768 21 kDa protein 1.141 0.190 
IPI00216318 Isoform Long of 14-3-3 protein beta/alpha 1.132 0.179 
IPI00028055 Transmembrane emp24 domain-containing protein 10 1.129 0.176 
IPI00440493 ATP synthase subunit alpha, mitochondrial 1.126 0.172 
IPI00027107 Tu translation elongation factor, mitochondrial precursor 1.126 0.171 
IPI00022020 Type II inositol-3,4-bisphosphate 4-phosphatase 1.121 0.165 
IPI00215998 CD63 antigen 1.120 0.164 
IPI00033600 Isoform 1 of Protein phosphatase 1 regulatory subunit 7 1.120 0.163 
IPI00024466 Isoform 1 of UDP-glucose:glycoprotein glucosyltransferase 1 1.118 0.161 
IPI00021174 Isoform Long of ADP-ribosylation factor-binding protein GGA3 1.117 0.160 
IPI00034049 Isoform 1 of Regulator of nonsense transcripts 1 1.115 0.157 
IPI00008529 60S acidic ribosomal protein P2 1.114 0.156 
IPI00438229 Isoform 1 of Transcription intermediary factor 1-beta 1.114 0.156 
IPI00719643 Putative uncharacterized protein SETX 1.113 0.155 
IPI00015602 Mitochondrial import receptor subunit TOM70 1.110 0.150 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 5. SILAC KSR1-downregulated phosphorylated proteins (– log2 
<0.15 fold). 
Protein IDs Protein Descriptions Normalised 
R10K8/R0K0 
Log2 
R10K8/R0K0 
IPI00022990 Statherin 0.059 -4.072 
IPI00004573 Polymeric immunoglobulin receptor 0.155 -2.692 
IPI00217049 Isoform p71 of 2-5-oligoadenylate synthetase 2 0.250 -1.999 
IPI00719752 Isoform 2 of Eukaryotic translation initiation factor 3 subunit B 0.509 -0.973 
IPI00026320 E3 ubiquitin-protein ligase UBR5 0.545 -0.875 
IPI00843759 Putative uncharacterized protein YTHDF1 0.553 -0.854 
IPI00333410 Isoform 1 of Ubiquitin-conjugating enzyme E2 Q1 0.565 -0.823 
IPI00012268 26S proteasome non-ATPase regulatory subunit 2 0.595 -0.748 
IPI00797230 32 kDa protein 0.601 -0.734 
IPI00456363 Isoform 3 of Ataxin-2-like protein 0.617 -0.696 
IPI00016608 Transmembrane emp24 domain-containing protein 2 0.633 -0.660 
IPI00010951 epiplakin 1 0.634 -0.657 
IPI00002441 Syndecan-1 0.651 -0.620 
IPI00027230 Endoplasmin 0.668 -0.582 
IPI00797384 Isoform 4 of La-related protein 4 0.671 -0.577 
IPI00328257 Isoform A of AP-1 complex subunit beta-1 0.675 -0.567 
IPI00000728 Isoform 1 of Ubiquitin carboxyl-terminal hydrolase 15 0.678 -0.561 
IPI00376394 Sulfhydryl oxidase 2 0.683 -0.549 
IPI00854642 Isoform 1 of Sister chromatid cohesion protein PDS5 homolog A 0.687 -0.542 
IPI00011229 Cathepsin D 0.687 -0.541 
IPI00847793 Dermcidin isoform 2 0.688 -0.539 
IPI00922415 
cDNA FLJ51825, highly similar to Single-stranded DNA-binding protein, 
mitochondrial 0.693 -0.530 
IPI00291783 Gem-associated protein 5 0.693 -0.529 
IPI00307572 Transmembrane protein 165 0.696 -0.524 
IPI00219774 cAMP-dependent protein kinase type II-alpha regulatory subunit 0.701 -0.512 
IPI00220301 Peroxiredoxin-6 0.707 -0.500 
IPI00925413 EIF4G1 protein 0.709 -0.496 
IPI00385267 Signal recognition particle receptor subunit alpha 0.717 -0.480 
IPI00607554 Isoform 1 of Ubiquitin carboxyl-terminal hydrolase 47 0.719 -0.476 
IPI00217354 Isoform 2 of ADP-ribosylation factor GTPase-activating protein 1 0.727 -0.460 
IPI00219077 Isoform 1 of Leukotriene A-4 hydrolase 0.730 -0.454 
IPI00795906 MHC class I antigen heavy chain 0.730 -0.453 
IPI00016095 Transcription termination factor, mitochondrial 0.734 -0.446 
IPI00032491 Inner nuclear membrane protein Man1 0.735 -0.445 
IPI00026991 Polypeptide N-acetylgalactosaminyltransferase 6 0.739 -0.436 
IPI00011609 Isoform II of Ubiquitin-protein ligase E3A 0.741 -0.432 
IPI00182757 Isoform 1 of Protein KIAA1967 0.748 -0.419 
IPI00256861 Isoform 2 of Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 0.749 -0.417 
IPI00216044 Isoform 1 of RNA-binding protein Raly 0.750 -0.414 
IPI00031812 Nuclease-sensitive element-binding protein 1 0.757 -0.402 
IPI00456969 Cytoplasmic dynein 1 heavy chain 1 0.762 -0.393 
IPI00030911 Vesicle-associated membrane protein 8 0.765 -0.387 
IPI00002255 Isoform 1 of Lipopolysaccharide-responsive and beige-like anchor protein 0.765 -0.386 
IPI00003843 cDNA FLJ53324, highly similar to Tight junction protein ZO-2 0.770 -0.377 
IPI00254162 cDNA FLJ55936, highly similar to Polypyrimidine tract-binding protein 2 0.772 -0.374 
IPI00953703 Putative uncharacterized protein GOLGA5 0.773 -0.371 
IPI00007426 PRA1 family protein 3 0.777 -0.365 
IPI00031420 UDP-glucose 6-dehydrogenase 0.777 -0.364 
IPI00010252 Isoform Alpha of E3 ubiquitin-protein ligase TRIM33 0.781 -0.356 
IPI00024993 Enoyl-CoA hydratase, mitochondrial 0.784 -0.352 
IPI00008524 Isoform 1 of Polyadenylate-binding protein 1 0.788 -0.344 
IPI00024976 Mitochondrial import receptor subunit TOM22 homolog 0.791 -0.339 
IPI00295252 
Isoform 1 of Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 
1 protein 0.797 -0.327 
IPI00019600 Ubiquitin-conjugating enzyme E2 variant 2 0.798 -0.326 
IPI00796337 poly(rC) binding protein 2 isoform a 0.798 -0.325 
IPI00784614 septin 9 isoform a 0.800 -0.323 
IPI00217540 Isoform 2 of Lysine-specific histone demethylase 1 0.803 -0.317 
IPI00413108 33 kDa protein 0.804 -0.315 
IPI00742743 Isoform 2 of Tumor suppressor p53-binding protein 1 0.813 -0.298 
IPI00036742 Isoform 1 of Protein virilizer homolog 0.814 -0.297 
IPI00465152 Transcription factor Sp1 0.816 -0.293 
IPI00020985 Histone acetyltransferase p300 0.818 -0.289 
IPI00815944 Isoform 3 of Treacle protein 0.822 -0.283 
IPI00029629 E3 ubiquitin/ISG15 ligase TRIM25 0.824 -0.280 
IPI00218782 cDNA FLJ60094, highly similar to F-actin capping protein subunit beta 0.825 -0.277 
IPI00026781 Fatty acid synthase 0.828 -0.273 
IPI00021048 Isoform 1 of Myoferlin 0.829 -0.270 
IPI00302927 T-complex protein 1 subunit delta 0.832 -0.265 
IPI00784414 Isoform 1 of Signal transducer and activator of transcription 3 0.834 -0.263 
IPI00479786 KH-type splicing regulatory protein 0.835 -0.260 
IPI00029012 Eukaryotic translation initiation factor 3 subunit A 0.845 -0.243 
IPI00386448 Isoform 1 of Transcription factor p65 0.848 -0.239 
IPI00514983 Heat shock 105kDa/110kDa protein 1, isoform CRA_b 0.850 -0.234 
IPI00013272 Isoform 1 of Golgin subfamily A member 4 0.850 -0.234 
IPI00016342 Ras-related protein Rab-7a 0.857 -0.223 
IPI00396378 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 0.857 -0.223 
IPI00333541 Isoform 1 of Filamin-A 0.858 -0.221 
IPI00186290 Elongation factor 2 0.861 -0.216 
IPI00083708 Isoform 7 of BAT2 domain-containing protein 1 0.861 -0.215 
IPI00032635 Isoform 1 of Protein LSM14 homolog B 0.863 -0.213 
IPI00216746 Isoform 2 of Heterogeneous nuclear ribonucleoprotein K 0.863 -0.213 
IPI00409717 Isoform 2 of Eukaryotic initiation factor 4A-II 0.863 -0.213 
IPI00915260 Isoform 1 of Cyclin-K 0.866 -0.208 
IPI00019380 Nuclear cap-binding protein subunit 1 0.867 -0.205 
IPI00022228 Vigilin 0.869 -0.202 
IPI00514856 Isoform 1 of Ubiquitin-associated protein 2-like 0.870 -0.201 
IPI00018813 Isoform 2 of COP9 signalosome complex subunit 2 0.871 -0.200 
IPI00412343 Isoform 6 of Fragile X mental retardation 1 protein 0.871 -0.199 
IPI00005737 Isoform 1 of Surfeit locus protein 4 0.871 -0.199 
IPI00293735 Elongator complex protein 1 0.872 -0.198 
IPI00383581 cDNA FLJ61290, highly similar to Neutral alpha-glucosidase AB 0.874 -0.195 
IPI00031819 UPF0139 membrane protein C19orf56 0.874 -0.194 
IPI00215914 ADP-ribosylation factor 1 0.878 -0.188 
IPI00473014 Destrin 0.881 -0.183 
IPI00294879 Ran GTPase-activating protein 1 0.884 -0.178 
IPI00178150 Isoform 1 of Chromosome-associated kinesin KIF4A 0.889 -0.170 
IPI00942869 Isoform 1ABC of Catenin delta-1 0.898 -0.156 
IPI00020984 cDNA FLJ55574, highly similar to Calnexin 0.898 -0.156 
IPI00219678 Eukaryotic translation initiation factor 2 subunit 1 0.898 -0.155 
IPI00409671 Isoform 1 of ATP-dependent RNA helicase DDX42 0.899 -0.154 
IPI00010740 Isoform Long of Splicing factor, proline- and glutamine-rich 0.900 -0.151 
IPI00026182 F-actin-capping protein subunit alpha-2 0.901 -0.151 
 
 
 
 
